Pharmacokinetic bioequivalence, safety and acceptability of Ornibel (R), a new polymer composition contraceptive vaginal ring (etonogestrel/ethinyl estradiol 11.00/3.474 mg) compared with Nuvaring (R) (etonogestrel /ethinylestradiol 11.7/2.7 mg)

摘要

Objective: To show the clinical development of Ornibel (R) (ExeltisHealthcare, Spain) a contraceptive vaginal ring manufactured with a new polymer composition and containing etonogestrel/ethinylestradiol, compared to Nuvaring (R) (MSD, Spain).